Atorvastatin calcium (DrugBank: Atorvastatin, Calcium)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 265 | Lipodystrophy | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00017758 (ClinicalTrials.gov) | June 2001 | 11/6/2001 | The Effect of Efavirenz and Nelfinavir on the Blood Levels of Certain Lipid-Lowering Drugs | The Effect of Efavirenz and Nelfinavir on the Pharmacokinetics of Hydroxymethylglutaryl Coenzyme A Reductase Inhibitors | HIV Infections;HIV Seronegativity;Lipodystrophy | Drug: Pravastatin sodium;Drug: Simvastatin;Drug: Atorvastatin calcium;Drug: Nelfinavir mesylate;Drug: Efavirenz | National Institute of Allergy and Infectious Diseases (NIAID) | NULL | Completed | 18 Years | 60 Years | Both | 56 | Phase 1 | United States |